FAU researchers spent five years studying the gut microbiomes of Northern cardinals, a common backyard songbird known for its vivid red plumage. Their study explores how microbiome diversity impacts the birds’ health, body condition, and ornamental traits, such as their coloration.
MD Anderson and AmMax Bio announced agreements to develop and advance AmMax's AMB-066 monoclonal antibody therapy for colorectal cancer with minimal residual disease.
With one IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the amount of blood the heart can pump and dramatically improves survival.
ISPOR—The Professional Society for Health Economics and Outcomes Research announced that it has launched a new microsite—HEOR Explained—designed to help people better understand how health economics and outcomes research (HEOR) can improve healthcare decisions.
Quitline coaching over the phone helped almost half of young people who vape ditch the habit, potentially improving their health and decreasing the chances they’ll transition to cigarettes, according to a new Ohio State study.
A majority of U.S. adults hope to avoid political discussions during the holidays and, in some cases, family members they disagree with, according to a survey by the American Psychological Association.
Patients with multiple myeloma are living longer thanks to a host of new immunotherapies and targeted drugs. But there is still no cure for the disease. Physician-scientists at Sylvester Comprehensive Cancer Center are working to change that, and will present research findings at the 2024 annual meeting of the American Society of Hematology (ASH).
Smokers with myelodysplastic syndromes or a precursor condition had elevated levels of genetic mutations linked to the disease. The study also found that heavier smokers accumulated more mutations, and long-term smokers were more likely to show disease progression.
Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias. The results were presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. More information on all ASH Annual Meeting content from MD Anderson can be found at MDAnderson.org/ASH.
Where did Earth’s water come from? It’s a fundamental scientific question that has never been answered. In fact, NASA reports that we can only observe and understand 5% of the universe — with a whopping 95% remaining a complete mystery because of unobservable dark matter and dark energy.
About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease advance or recur following treatment. Seeking a new treatment strategy that might boost the effectiveness of existing DLBCL therapies, a team from Roswell Park has been working to understand the underlying mechanisms of the targeted chemotherapy venetoclax. Their findings, to be presented during a talk today at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California, provide strong preclinical evidence that adding venetoclax to standard treatment may improve outcomes in patients with treatment-resistant B-cell lymphomas.
As the school year winds up, thousands of Aussie kids are looking forward to the summer holidays. But hand-in hand with this freedom comes an abundance of screentime, unhealthy snacks, and a lack of routine, and it has the potential to affect children’s physical and mental health.
Community leaders and entrepreneurs are among the newest members of Cal State Fullerton’s Philanthropic Foundation Board of Governors, the nonprofit auxiliary organization established to build and strengthen CSUF’s relations with the community and encourage advocacy, investment in and support of the university.
A study sheds new light on how Toxoplasma gondii parasites make the proteins they need to enter a dormant stage that allows them to escape drug treatment.
Dave Grabaskas, Paul Romano, Ben Lindley and April Novak are recognized by American Nuclear Society on Nuclear News’ highly selective list of rising stars in nuclear research
Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
